Introduction:
Pharma stock launched Latanoprost Ophthalmic Solution, 0.005%, a bioequivalent to Xalatan®. The drug targets glaucoma and ocular hypertension, expanding its U.S. market. This launch strengthens its ophthalmic portfolio and enhances growth opportunities in the vision care industry.
Share Price movement of Glenmark Pharmaceuticals:
On February 14, 2025, Glenmark Pharmaceuticals Limited opened at ₹1,416.95, reaching a high of ₹1,437.35 and a low of ₹1,357.35, down 3.81% from its previous close of ₹1,411.20. Currently, it is trading at ₹1,357.45, with a market cap of ₹38,305.63 crore.
Glenmark Pharmaceuticals new launch:
Glenmark Pharmaceuticals Inc., USA, launched Latanoprost Ophthalmic Solution, 0.005%, a generic version of Xalatan®. This bioequivalent alternative enhances Glenmark’s ophthalmic portfolio. The launch provides an affordable treatment for patients with intraocular pressure issues.
The solution is intended for open-angle glaucoma and ocular hypertension. Glenmark aims to expand its U.S. ophthalmic market presence. This reinforces its commitment to accessible, high-quality generics.
IQVIA data shows Xalatan® Ophthalmic Solution’s market reached $113.5 million in annual sales. Glenmark’s entry strengthens its position in the ophthalmic sector. This launch offers growth opportunities in the competitive vision care industry.
Recent news About Glenmark Pharmaceuticals :
January 21, 2025, the company introduced Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules. This product is indicated for the prevention and treatment of hypoprothrombinemia caused by vitamin K deficiency or interference with vitamin K activity.
Ace investor holding of Glenmark Pharmaceuticals:
Ace investor Ashish Dhawan holds a 1.88% stake in Glenmark Pharmaceuticals, owning 53 lakh shares valued at ₹722.0 crore. His holding saw a slight reduction of 0.67% from the previous quarter, reflecting portfolio adjustments while maintaining significant exposure to the pharma sector.
Stock performance of Glenmark Pharmaceuticals for Period of 1 week, 6 months and 1 year:
Glenmark Pharmaceuticals’ stock declined 8.37% over the past week, reflecting short-term volatility. Over six months, it dropped 9.87%, indicating a moderate downtrend. However, the stock delivered a strong 74.2% gain over the past year, showcasing long-term growth despite recent fluctuations in performance.
Also Read: Bank stock jumps after Zulia Investments Pte to acquire 7% stake in the company
Shareholding pattern of Glenmark Pharmaceuticals:
| Summary | Dec-24 | Sep-24 | Jun-24 |
| Promoter | 46.70% | 46.70% | 46.70% |
| FII | 23.50% | 23.10% | 21.00% |
| DII | 13.90% | 13.30% | 14.00% |
| Public | 16.00% | 17.10% | 18.40% |
About Glenmark Pharmaceuticals:
Glenmark Pharmaceuticals is a global pharmaceutical company specializing in generics, specialty, and over-the-counter medicines. It focuses on dermatology, respiratory, and oncology segments. With a strong presence in regulated markets like the U.S. and Europe, it continues expanding its research-driven pipeline and biosimilar offerings.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.
